Imatinib attenuates astrogliosis and CSPG deposition.

<p>(<b>A</b>) Representative micrographs of dorsomedial GFAP immunoreactivity 14 mm caudal to the injury site at 5 and 56 days post-injury. (<b>B</b>) Representative micrographs of CS56 immunoreactivity within the injury site at day 5 post-injury. (<b>C</b>) Quantification of CS56 immunoreactivity within the injury site and spinal segments 7 and 14 mm rostral and caudal to the injury at day 5. (<b>D</b>) Representative micrographs of NG2 immunoreactivity within the injury site at day 5 post-injury. (<b>E</b>) Quantification of NG2 immunoreactivity within the injury site and in spinal segments 7 to 14 mm rostral and caudal to the injury site at day 5. Imatinib (day 5, N = 4; day 56, N = 6) compared to PBS (day 5, N = 4; day 56, N = 6). Data presented as mean ± SD: *P<0.05, **P<0.01, and ***P<0.001. Scale bars: 100 µm.